Literature DB >> 1614590

Single intracisternal bolus of recombinant tissue plasminogen activator in patients with aneurysmal subarachnoid hemorrhage: preliminary assessment of efficacy and safety in an open clinical study.

D Stolke1, V Seifert.   

Abstract

Intracisternal thrombolysis with recombinant tissue plasminogen activator (rtPA) was performed in 20 patients with aneurysmal subarachnoid hemorrhage. All patients had blood accumulations in the basal cisterns according to Fisher's Grade III, thus being at a high risk for the development of posthemorrhagic delayed ischemic deficits (DID). All patients underwent an operation within 72 hours after aneurysm rupture. After the aneurysm had been excluded from the cerebral circulation, a single bolus of 10 mg of rtPA was injected into the basal cisterns. Postoperatively, serial computed tomographic examinations demonstrated radical blood clot removal in all patients. Daily transcranial Doppler examinations revealed accelerated blood flow velocities in 16 of 20 patients. The postoperative results according to the Glasgow Outcome Scale were as follows: 16 patients were Grades I and II, 2 patients were Grade III. Two patients died postoperatively, 1 because of a bowel perforation, and 1 from DID attributable to the development of a cerebral vasospasm. No postoperative bleeding complications occurred. It is concluded that pharmacological removal of subarachnoid blood accumulations can be achieved in a safe and effective way by an intrathecal single bolus of 10 mg of rtPA instilled into the basal cisterns after aneurysm clipping. The acceleration of blood flow velocities in a number of patients indicated that posthemorrhagic arterial narrowing was not completely prevented by this treatment, but this remained asymptomatic in 19 of 20 patients. Although extensive blood clot removal can be achieved by a single bolus of rtPA, more radical or complete blood removal probably requires the use of higher drug concentrations or additional postoperative intracisternal or intraventricular rtPA injections, for which further studies are needed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614590     DOI: 10.1227/00006123-199206000-00010

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  9 in total

1.  Endogenous tissue plasminogen activator in neonatal cerebrospinal fluid.

Authors:  A Whitelaw; M C Mowinckel; V Fellman; U Abildgaard
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

2.  Thrombolysis for intraventricular hemorrhage after endovascular aneurysmal coiling.

Authors:  Bradley Hall; Dennis Parker; J Ricardo Carhuapoma
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Lysis of basal ganglia haematoma with recombinant tissue plasminogen activator (rtPA) after stereotactic aspiration: initial results.

Authors:  B E Lippitz; L Mayfrank; U Spetzger; J P Warnke; H Bertalanffy; J M Gilsbach
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

4.  "Head-shaking syndrome" neurological deterioration during continuous head-shaking as an adjunct to cisternal irrigation for clot removal in patients with acute subarachnoid haemorrhage.

Authors:  N Aoki
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Effect of recombinant tissue plasminogen activator on clot lysis and ventricular dilatation in the treatment of severe intraventricular haemorrhage.

Authors:  L Mayfrank; B Lippitz; M Groth; H Bertalanffy; J M Gilsbach
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

Review 6.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

7.  Is there a difference in cognitive deficits after aneurysmal subarachnoid haemorrhage and subarachnoid haemorrhage of unknown origin?

Authors:  B O Hütter; J M Gilsbach; I Kreitschmann
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Prevention of delayed ischaemic deficits after aneurysmal subarachnoid haemorrhage by intrathecal bolus injection of tissue plasminogen activator (rTPA). A prospective study.

Authors:  V Seifert; D Stolke; M Zimmermann; A Feldges
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

9.  Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus.

Authors:  A Whitelaw; E Saliba; V Fellman; M C Mowinckel; D Acolet; N Marlow
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-07       Impact factor: 5.747

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.